Sonoma Pharmaceuticals (SNOA) Cash from Investing Activities (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Cash from Investing Activities of -$29000.0 for Q1 2026, up 38.3% year-over-year from -$20969.2 in Q1 2025, and up 38.3% quarter-over-quarter from -$47000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$29000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 38.3% year-over-year to -$29000.0; the TTM figure through Mar 2026 stood at -$192000.0 (down 140.0% YoY), while the FY2026 annual figure was -$192000.0, down 140.0% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$29000.0, up from -$47000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $34000.0 in Q4 2022, with the low at -$187000.0 in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$23000.0 (2022), against an average of -$34882.4.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities surged 121.95% in 2024, then slumped 2250.0% in 2025.
- Sonoma Pharmaceuticals' Cash from Investing Activities stood at $34000.0 in 2022, then tumbled by 102.94% to -$1000.0 in 2023, then sank by 100.0% to -$2000.0 in 2024, then plunged by 2250.0% to -$47000.0 in 2025, then surged by 38.3% to -$29000.0 in 2026.
- Business Quant data shows SNOA's Cash from Investing Activities at -$29000.0 in Q1 2026, -$47000.0 in Q4 2025, and -$10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.12 Mn | -222,819.83 | 2.58 Mn | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,000.00 |
| Jun 30, 2026 | -2,000.00 |
| Mar 31, 2026 | -29,000.00 |
| Mar 31, 2026 | -29,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -106,000.00 |
| Jun 30, 2025 | -106,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Mar 31, 2024 | 18,000.00 |